Celltrion and Teva look set to get a biosimilar of Roche’s blockbuster MabThera/Rituxan (rituximab) onto the US market ahead of rivals.
Rituximab went off patent in the US last year, leaving it open to competition from cheaper biosimilar versions.
It is Roche’s biggest selling drug, generating around $7.3 billion in sales in 2016, and more than $3.9 billion of this revenue was based in the US.
It is used in non-Hodgkin’s lymphoma, chronic lymphocytic leukaemia, rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis ......


Read more here: https://pharmaphorum.com/news/celltr...biosimilar-us/